Oncopharmpod
Tarlatamab
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:10:12
- Mas informaciones
Informações:
Sinopsis
A new drug for small-cell lung cancer, a bispecific, targeting DLL3 on small-cell lung cancer and CD3 on T-cells is FDA approved. But, infigratinib's FDA approval for cholangiocarcinoma is withdrawn.
